EX-10.11
Scribe Therapeutics, Inc.
Execution Copy
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SCRIBE THERAPEUTICS INC. IF PUBLICLY DISCLOSED.
Development and Option Agreement
by and between
ACUITAS THERAPEUTICS, INC.
and
SCRIBE THERAPEUTICS INC.
dated
November 7, 2022
TABLE OF CONTENTS
Page
Article 1 Definitions
1
Article 2 Governance
9
2.1
Management
9
2.2
Joint Development Committee
9
Article 3 The Program
10
3.1
Program Generally
10
3.2
FTEs
12
3.3
Program Records, Reports and Materials
13
3.4
Program Licenses
14
Article 4 Reserved Targets
16
4.1
Generally
16
4.2
Reserved Protein Target List, Restricted Protein Target List and Protein Target Notices
16
4.3
Expiration of Pre-Existing Restrictions
17
4.4
Fees
17
…